Analysis of Outcome Measures in Patients with a Fragility Fracture Treated with Forteo

Presentation Type

Oral and/or Visual Presentation

Presenter Major(s)

Physician Assistant Studies

Mentor Information

Theresa Bacon-Baguley, bacon-bt@gvsu.edu

Department

Physician Assistant Studies

Location

Kirkhof Center 2216

Start Date

13-4-2011 11:00 AM

End Date

13-4-2011 11:30 AM

Keywords

Health, Illness, and Healing

Abstract

It is estimated that 10 million Americans have osteoporosis with an additional 34 million having a low bone mass density putting them at risk for the development of osteoporosis. The pathology of osteoporosis revolves around a disruption in bone metabolism which involves a cyclic process of bone resorption (breakdown) and bone formation. These processes, bone resorption and bone formation, can be monitored through serum and/or urine bone markers. One of the treatments for individuals who have sustained a fragility fracture due to osteoporosis is Forteo@, a recombinant human parathyroid hormone. The purpose of this study was to determine the change in bone mineral density and physiologic markers for bone metabolism in patients diagnosed with osteoporosis who were treated with Forteo@.

This document is currently not available here.

Share

COinS
 
Apr 13th, 11:00 AM Apr 13th, 11:30 AM

Analysis of Outcome Measures in Patients with a Fragility Fracture Treated with Forteo

Kirkhof Center 2216

It is estimated that 10 million Americans have osteoporosis with an additional 34 million having a low bone mass density putting them at risk for the development of osteoporosis. The pathology of osteoporosis revolves around a disruption in bone metabolism which involves a cyclic process of bone resorption (breakdown) and bone formation. These processes, bone resorption and bone formation, can be monitored through serum and/or urine bone markers. One of the treatments for individuals who have sustained a fragility fracture due to osteoporosis is Forteo@, a recombinant human parathyroid hormone. The purpose of this study was to determine the change in bone mineral density and physiologic markers for bone metabolism in patients diagnosed with osteoporosis who were treated with Forteo@.